Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine
- 1 November 1991
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 91 (5) , 471-478
- https://doi.org/10.1016/0002-9343(91)90182-w
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) InfectionAnnals of Internal Medicine, 1990
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related ComplexPublished by American Medical Association (AMA) ,1989
- Clinical Pharmacology of 3'-Azido-2',3'-Dideoxythymidine (Zidovudine) and Related DideoxynucleosidesNew England Journal of Medicine, 1989
- Nature, time course and dose dependence of zidovudine-related side effectsAIDS, 1989
- Survival Experience Among Patients With AIDS Receiving ZidovudinePublished by American Medical Association (AMA) ,1988
- The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Strategies for antiviral therapy in AIDSNature, 1987
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEXThe Lancet, 1986